Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Feb 20, 2020- Data at ATTD reinforce and add to a growing body of clinical research and real-world evidence from users of the FreeStyle Libre system around the world- People in Germany living with Type 1 or Type 2 diabetes on insulin showed a sustained reduction in HbA1c over one year following use of the FreeStyle Libre technology
Feb 19, 2020- Collaboration will combine Abbott's leading continuous glucose monitoring (CGM) technology with Insulet's Omnipod Horizon™ Automated Insulin Delivery System to offer an accurate, easy-to-use, integrated digital health platform- Integrated technology will provide people living with diabetes around the world an affordable, transformational experience for improved glucose control- Feb 18, 2020- New Gallant™ high voltage devices offer patients and their doctors a smartphone app and Bluetooth connectivity designed to help doctors tailor therapy to a patient's unique clinical needs- Gallant ICD and CRT-D devices feature a more comfortable design, preferred by patients without compromising on battery longevity or high-voltage output, which remain among the highest in the industry
- Feb 3, 2020- The CATALYST trial will examine Abbott's Amplatzer™ Amulet™ device compared to non-vitamin K oral anticoagulants, the current standard in attempting to lower stroke and bleeding risks for patients with atrial fibrillation
- Jan 30, 2020- First-of-its-kind technology addresses critical need to eliminate mitral regurgitation when surgery or mitral repair is not an option- Tendyne valve provides relief from heart failure symptoms and quality-of-life improvement in high-surgical-risk patients- Together with MitraClip™, Tendyne expands Abbott's market-leading portfolio of innovative minimally invasive mitral valve solutions
- Jan 24, 2020- Abbott's Infinity™ DBS is the first FDA approved directional Deep Brain Stimulation (DBS) system to allow targeting of a specific area of the brain that is critical to motor functions- Approximately 60,000 Americans are diagnosed with Parkinson's disease each year[i]
- Jan 23, 2020- BOLD study found that BurstDR™ stimulation waveform reduced the negative psychological effects associated with a person's chronic pain at six-month follow up by 62%- Data were presented at the 2020 North American Neuromodulation Society (NANS) annual meeting- Proclaim XR uses Abbott's proprietary BurstDR technology to achieve chronic pain relief
- Jan 22, 2020- Fourth-quarter sales growth of 7.1 percent; organic sales growth of 8.5 percent- Fourth-quarter GAAP EPS growth from continuing operations of 59.5 percent and adjusted EPS growth from continuing operations of 17.3 percent- Several businesses achieved double-digit sales growth- Forecast reflects continued top-tier sales and earnings growth for 2020